Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

13.31
+0.39503.06%
Pre-market: 13.580.2678+2.01%05:08 EDT
Volume:14.82M
Turnover:194.74M
Market Cap:6.03B
PE:-18.86
High:13.40
Open:12.65
Low:12.62
Close:12.92
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.01
T/O Rate:3.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:8.19
PE(LYR):-12.17

Loading ...

May 22, 2020

Major Issues Report

8-K - Current report
May 08, 2020

Major Issues Report

Current report, items 8.01 and 9.01
May 05, 2020

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
May 05, 2020

Major Issues Report

Current report, items 2.02 and 9.01
Feb 25, 2020

Annual Report

Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 25, 2020

Major Issues Report

Current report, items 2.02 and 9.01
Feb 24, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2020

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Feb 14, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 11, 2020

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Feb 05, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 04, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 04, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Nov 04, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Sep 20, 2019

Correspondence

[Cover]Correspondence
Sep 17, 2019

Correspondence

[Cover]Correspondence
Aug 01, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Aug 01, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Jul 19, 2019

Statement Of Changes In Beneficial Ownership

Initial statement of beneficial ownership of securities